Skip to content
10-Q

Quarterly Report

Ambrx Biopharma Inc.

0000950170-23-021219

← back to feed
Filed
May 11, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 8, 2023 386.61M sh
Shares Diluted Q1 2023 · Mar 31, 2023 314.97M sh
Shares Diluted Q1 2023 · Mar 31, 2022 270.12M sh
Capex Q1 2023 · Mar 31, 2023 $0
Capex Q1 2023 · Mar 31, 2022 $774K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$12.97M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$25.66M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $149.58M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $143.63M
Stockholders Equity Q1 2023 · Mar 31, 2023 $182.59M
Stockholders Equity Q1 2023 · Dec 31, 2022 $117.85M
Stockholders Equity Q1 2023 · Mar 31, 2022 $168.98M
Stockholders Equity Q1 2023 · Dec 31, 2021 $189.97M
Current Liabilities Q1 2023 · Mar 31, 2023 $16.09M
Current Liabilities Q1 2023 · Dec 31, 2022 $16.66M
Total Liabilities Q1 2023 · Mar 31, 2023 $28.02M
Total Liabilities Q1 2023 · Dec 31, 2022 $29.13M
Current Assets Q1 2023 · Mar 31, 2023 $162.94M
Current Assets Q1 2023 · Dec 31, 2022 $90.58M
Total Assets Q1 2023 · Mar 31, 2023 $210.61M
Total Assets Q1 2023 · Dec 31, 2022 $146.98M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.05
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.08
Eps Basic Q1 2023 · Mar 31, 2023 −$0.05
Eps Basic Q1 2023 · Mar 31, 2022 −$0.08
Sga Expense Q1 2023 · Mar 31, 2023 $6.31M
Sga Expense Q1 2023 · Mar 31, 2022 $4.57M
Rd Expense Q1 2023 · Mar 31, 2023 $9.75M
Rd Expense Q1 2023 · Mar 31, 2022 $14.7M
Net Income Q1 2023 · Mar 31, 2023 −$15.3M
Net Income Q1 2023 · Mar 31, 2022 −$22.65M
Operating Income Q1 2023 · Mar 31, 2023 −$16.03M
Operating Income Q1 2023 · Mar 31, 2022 −$20.13M
Revenue Q1 2023 · Mar 31, 2023 $24K
Revenue Q1 2023 · Mar 31, 2022 $1.61M